Aspire Biopharma Effectuates 1-for-30 Reverse Stock Split

summarizeSummary

Aspire Biopharma Holdings, Inc. has officially effectuated a 1-for-30 reverse stock split, a key action to boost its share price and maintain exchange listing requirements.

check_boxKey Events · Corporate Governance and Compliance · ASBP

• Reverse Stock Split Effectuated

  On May 11, 2026, Aspire Biopharma Holdings, Inc. filed a Certificate of Amendment to its Certificate of Incorporation to effect a 1-for-30 reverse stock split.

• Share Consolidation

  Every thirty (30) shares of common stock outstanding prior to the effective time will automatically be combined and converted into one (1) share of common stock. Fractional shares will be rounded up to the nearest whole share.

• Aimed at Listing Compliance

  This action is a common strategy for micro-cap companies to increase their per-share price, often to meet minimum bid price requirements of stock exchanges like Nasdaq and avoid delisting.

• Follows Prior Approvals

  This implementation follows shareholder approval of the reverse stock split on April 16, 2026, as previously disclosed in an 8-K filing.

auto_awesomeAnalysis · ASBP · Life Sciences

Aspire Biopharma Holdings, Inc. has officially implemented a 1-for-30 reverse stock split, a critical move for this micro-cap company. This action, which follows prior shareholder approvals, is typically undertaken to increase the per-share price and meet exchange listing requirements, thereby preventing potential delisting. While reverse splits are often viewed negatively, this is a necessary step for the company to maintain its market presence and potentially facilitate future financing, especially given its recent history of dilutive capital raises.